T
Talmadge E. King
Researcher at University of California, San Francisco
Publications - 215
Citations - 48569
Talmadge E. King is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Interstitial lung disease. The author has an hindex of 88, co-authored 214 publications receiving 43290 citations. Previous affiliations of Talmadge E. King include National Jewish Health & University of California.
Papers
More filters
Journal ArticleDOI
Prognostic Significance of Bronchoalveolar Lavage Cellular Analysis in Scleroderma Lung Disease
Brent W. Kinder,Talmadge E. King +1 more
Proceedings ArticleDOI
Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY
Steven D. Nathan,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Roland M. du Bois,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,David Kardatzke,Talmadge E. King,Klaus-Uwe Kirchgaessler,Lisa Lancaster,David J. Lederer,Carlos Alberto de Castro Pereira,Jeffrey J. Swigris,Dominique Valeyre,Paul W. Noble +16 more
TL;DR: A pooled analysis of the ASCEND and CAPACITY studies showed a significant reduction in the risk of TE ACM over 52 weeks in patients with IPF treated with pirfenidone compared with placebo, and a non-significant trend favoring pirfenide over the entire study period (up to week 120) as discussed by the authors.
Journal Article
Waldenström's Macroglobulinemia: Report of a Case With Pulmonary Involvement and Recurrent Pneumococcal Sepsis After Pneumococcal Vaccination
TL;DR: A patient with Waldenström's macroglobulinemia who presented with pleuropulmonary manifestations was complicated by recurrent Streptococcus pneumoniae infections despite pneumococcal immunization.
Proceedings ArticleDOI
A Double-Blind, Placebo-Controlled, Randomized Trial Of Combined Prednisone, Azathioprine And N-Acetylcysteine In Idiopathic Pulmonary Fibrosis
Journal Article
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Dominique Valeyre,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Talmadge E. King,Paul W. Noble,Steven A. Sahn,Roland M. du Bois +7 more
TL;DR: Analysis of safety data from IPF patients receiving PFD for up to 7.7 years demonstrates that long-term treatment with PFD is safe and generally well tolerated.